-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Benzinga·06/23/2026 16:32:31
Listen to the news
HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.